JAMA Ophthalmology : Cost-effectiveness of Aflibercept vs Bevacizumab-First Therapy for Diabetic Macular Edema

JAMA Network - A podcast by The JAMA Network

Categories:

Science & Medicine

Interview with David W. Hutton, PhD, author of Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema. Hosted by Neil Bressler, MD.